TScan Therapeutics (TCRX) Debt to Equity (2022 - 2025)
Historic Debt to Equity for TScan Therapeutics (TCRX) over the last 4 years, with Q3 2025 value amounting to $0.23.
- TScan Therapeutics' Debt to Equity rose 6823.61% to $0.23 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.23, marking a year-over-year increase of 6823.61%. This contributed to the annual value of $0.13 for FY2024, which is 3317.23% down from last year.
- Latest data reveals that TScan Therapeutics reported Debt to Equity of $0.23 as of Q3 2025, which was up 6823.61% from $0.18 recorded in Q2 2025.
- In the past 5 years, TScan Therapeutics' Debt to Equity ranged from a high of $0.38 in Q1 2023 and a low of $0.12 during Q2 2024
- Its 4-year average for Debt to Equity is $0.2, with a median of $0.18 in 2025.
- Data for TScan Therapeutics' Debt to Equity shows a peak YoY increase of 6823.61% (in 2025) and a maximum YoY decrease of 3775.61% (in 2025) over the last 5 years.
- Quarter analysis of 4 years shows TScan Therapeutics' Debt to Equity stood at $0.29 in 2022, then crashed by 32.39% to $0.2 in 2023, then tumbled by 33.17% to $0.13 in 2024, then skyrocketed by 69.1% to $0.23 in 2025.
- Its Debt to Equity stands at $0.23 for Q3 2025, versus $0.18 for Q2 2025 and $0.15 for Q1 2025.